Skip to content
DataLookout
Menu

NCT01327781

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 131 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 55 words
    • Study completion pushed from Oct 30, 2026 to Oct 13, 2027
    • Secondary endpoints: details revised at 1 of 3 entries
    • Study description revised
  2. Minor Study completion date: Oct 30, 2025 to Oct 30, 2026v94
  3. Minor Study completion date: Oct 30, 2024 to Oct 30, 2025v91
  4. Minor Study completion date: Oct 30, 2024v87
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

MTD defined as the highest dose level where at most 1 of 6 patients develops a dose limiting toxicity and 2 or more of the 3-6 patients treated at the next higher dose level develop a dose limiting toxicity
Timeframe: 28 days

Secondary (3)

Progression-free survival
Overall survival
Change in hot flash scores graded using a hot flash diary and the hot flash interference scale

Arms and interventions

Treatment (Z-endoxifen hydrochloride)Experimental

Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drugs: Endoxifen Hydrochloride

Other: Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration

Sites

3 sites in 1 country